(NASDAQ: KZR) Kezar Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.72%.
Kezar Life Sciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast KZR's revenue for 2029 to be $145,896,826, with the lowest KZR revenue forecast at $145,896,826, and the highest KZR revenue forecast at $145,896,826. On average, 1 Wall Street analysts forecast KZR's revenue for 2030 to be $658,763,986, with the lowest KZR revenue forecast at $658,763,986, and the highest KZR revenue forecast at $658,763,986.
In 2031, KZR is forecast to generate $1,320,231,118 in revenue, with the lowest revenue forecast at $1,320,231,118 and the highest revenue forecast at $1,320,231,118.